# A Study to Assess the Safety and Efficacy of a Tacrolimus Based Immunosuppressive Regimen in Stable Kidney Transplant Recipients Converted From Cyclosporine Based Immunosuppressive Regimen

> **NCT02963103** · PHASE4 · TERMINATED · sponsor: **Astellas Pharma Korea, Inc.** · enrollment: 13 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT02963103
- **Lead sponsor:** Astellas Pharma Korea, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-05
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Sponsor decision to terminate the study because subject enrollment was difficult.
- **Last updated:** 2016-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02963103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02963103, "A Study to Assess the Safety and Efficacy of a Tacrolimus Based Immunosuppressive Regimen in Stable Kidney Transplant Recipients Converted From Cyclosporine Based Immunosuppressive Regimen". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02963103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*